Comparison of the in vivo induction and transmission of α-synuclein pathology by mutant α-synuclein fibril seeds in transgenic mice

Human Molecular Genetics

Volumn 26, Issue 24, 2017, Pages 4906-4915

  Rutherford, Nicola J ^a   Dhillon, Jess Karan S ^a   Riffe, Cara J ^a   Howard, Jasie K ^a   Brooks, Mieu ^a   Giasson, Benoit I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MUTANT PROTEIN; SNCA PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HIPPOCAMPUS; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUSCLE FIBRIL; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; SYNUCLEINOPATHY; ANIMAL; CELL INCLUSION; DEGENERATIVE DISEASE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PARKINSON DISEASE; PHYSIOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; CENTRAL NERVOUS SYSTEM; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMANS; INCLUSION BODIES; MICE; MICE, TRANSGENIC; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE;

EID: 85039158302     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddx371     Document Type: Article

References (59)

1. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J. et al. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov. Disord., 28, 811-813
2. Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet, 364, 1167-1169
3. Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A.J., Hardy, J. et al. (2013) α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol., 125, 753-769
4. Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J.T., Schöls, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet., 18, 106-108
5. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honoré, A., Rozas, N., Pieri, L., Madiona, K., Dürr, A., Melki, R. et al. (2013) G51D a-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol., 73, 459-471
6. Pasanen, P., Myllykangas, L., Siitonen, M., Raunio, A., Kaakkola, S., Lyytinen, J., Tienari, P.J., Pöyhönen, M. and Paetau, A. (2014) A novel a-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol. Aging, 35, 2180.e1-2185
7. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047
8. Proukakis, C., Dudzik, C.G., Brier, T., MacKay, D.S., Cooper, J.M., Millhauser, G.L., Houlden, H. and Schapira, A.H. (2013) A novel a-synuclein missense mutation in Parkinson disease. Neurology, 80, 1062-1064
9. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al. (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science, 302, 841
10. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B. et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol., 55, 164-173
11. Clayton, D.F. and George, J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res., 58, 120-129
12. Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998) Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem., 273, 9443-9449
13. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840
14. Waxman, E.A. and Giasson, B.I. (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim. Biophys. Acta, 1792, 616-624
15. Goedert, M., Spillantini, M.G., Del Tredici, K. and Braak, H. (2013) 100 years of Lewy pathology. Nat. Rev. Neurol., 9, 13-24
16. Cookson, M.R. (2005) The biochemistry of Parkinson's disease. Annu. Rev. Biochem., 74, 29-52
17. Hashimoto, M. and Masliah, E. (1999) Alpha-synuclein in Lewy body disease and Alzheimer's disease. Brain Pathol., 9, 707-720
18. Lippa, C.F., Fujiwara, H., Mann, D.M., Giasson, B., Baba, M., Schmidt, M.L., Nee, L.E., O'Connell, B., Pollen, D.A., St George-Hyslop, P., et al. (1998) Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol., 153, 1365-1370
19. Spillantini, M.G., Crowther, R.A., Jakes, R., Cairns, N.J., Lantos, P.L. and Goedert, M. (1998) Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci. Lett., 251, 205-208
20. Tu, P.H., Galvin, J.E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J.Q. and Lee, V.M. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann. Neurol., 44, 415-422
21. Conway, K.A., Harper, J.D. and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat. Med., 4, 1318-1320
22. Ghosh, D., Mondal, M., Mohite, G.M., Singh, P.K., Ranjan, P., Anoop, A., Ghosh, S., Jha, N.N., Kumar, A. and Maji, S.K. (2013) The Parkinson's disease-associated H50Q mutation accelerates a-synuclein aggregation in vitro. Biochemistry, 52, 6925-6927
23. Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J. Biol. Chem., 274, 7619-7622
24. Li, J., Uversky, V.N. and Fink, A.L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 40, 11604-11613
25. Narhi, L., Wood, S.J., Steavenson, S., Jiang, Y., Wu, G.M., Anafi, D., Kaufman, S.A., Martin, F., Sitney, K., Denis, P. et al. (1999) Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem., 274, 9843-9846
26. Rutherford, N.J., Moore, B.D., Golde, T.E. and Giasson, B.I. (2014) Divergent effects of the H50Q and G51D SNCA mutations on the aggregation of a-synuclein. J. Neurochem., 131, 859-867
27. Dhavale, D.D., Tsai, C., Bagchi, D.P., Engel, L.A., Sarezky, J. and Kotzbauer, P.T. (2017) A sensitive assay reveals structural requirements for alpha-synuclein fibril growth. J. Biol. Chem., 292, 9034-9050
28. Fares, M.-B., Ait-Bouziad, N., Dikiy, I., Mbefo, M.K., Jovicić, A., Kiely, A., Holton, J.L., Lee, S.-J., Gitler, A.D., Eliezer, D., et al. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of a-synuclein, and enhances its secretion and nuclear localization in cells. Hum. Mol. Genet., 23, 4491-4509
29. Ghosh, D., Sahay, S., Ranjan, P., Salot, S., Mohite, G.M., Singh, P.K., Dwivedi, S., Carvalho, E., Banerjee, R., Kumar, A. et al. (2014) The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates a-synuclein aggregation and membrane binding. Biochemistry, 53, 6419-6421
30. Rutherford, N.J. and Giasson, B.I. (2015) The A53E a-synuclein pathological mutation demonstrates reduced aggregation propensity in vitro and in cell culture. Neurosci. Lett., 597, 43-48
31. Choi, W., Zibaee, S., Jakes, R., Serpell, L.C., Davletov, B., Crowther, R.A. and Goedert, M. (2004) Mutation E46K increases phospholipid binding and assembly into filaments of human alpha-synuclein. FEBS Lett., 576, 363-368
32. Fredenburg, R.A., Rospigliosi, C., Meray, R.K., Kessler, J.C., Lashuel, H.A., Eliezer, D. and Lansbury, P.T. (2007) The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry, 46, 7107-7118
33. Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R., Englander, S.W., Axelsen, P.H. and Giasson, B.I. (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J. Biol. Chem., 280, 7800-7807
34. Ono, K., Ikeda, T., Takasaki, J. and Yamada, M. (2011) Familial Parkinson disease mutations influence a-synuclein assembly. Neurobiol. Dis., 43, 715-724
35. El-Agnaf, O.M., Jakes, R., Curran, M.D. and Wallace, A. (1998) Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease. FEBS Lett., 440, 67-70
36. Kamiyoshihara, T., Kojima, M., Uéda, K., Tashiro, M. and Shimotakahara, S. (2007) Observation of multiple intermediates in alpha-synuclein fibril formation by singular value decomposition analysis. Biochem. Biophys. Res. Commun., 355, 398-403
37. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and Lansbury, P.T. Jr (2000) Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A., 97, 571-576
38. Wood, S.J., Wypych, J., Steavenson, S., Louis, J.C., Citron, M. and Biere, A.L. (1999) alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J. Biol. Chem., 274, 19509-19512
39. Uchihara, T. and Giasson, B.I. (2016) Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol., 131, 49-73
40. Guo, J.L. and Lee, V.M.Y. (2014) Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nat. Med., 20, 130-138
41. Goedert, M., Clavaguera, F. and Tolnay, M. (2010) The propagation of prion-like protein inclusions in neurodegenerative diseases. Trends Neurosci., 33, 317-325
42. Goedert, M., Masuda-Suzukake, M. and Falcon, B. (2017) Like prions: the propagation of aggregated tau and a-synuclein in neurodegeneration. Brain, 140, 266-278
43. Luk, K.C., Kehm, V.M., Zhang, B., O'Brien, P., Trojanowski, J.Q. and Lee, V.M.Y. (2012) Intracerebral inoculation of pathological a-synuclein initiates a rapidly progressive neurodegenerative a-synucleinopathy in mice. J. Exp. Med., 209, 975-986
44. Rutherford, N.J., Sacino, A.N., Brooks, M., Ceballos-Diaz, C., Ladd, T.B., Howard, J.K., Golde, T.E. and Giasson, B.I. (2015) Studies of lipopolysaccharide effects on the induction of a-synuclein pathology by exogenous fibrils in transgenic mice. Mol. Neurodegener., 10, 32
45. Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., McGarvey, N.H., Rutherford, N.J., Ceballos-Diaz, C., Robertson, J., Golde, T.E. and Giasson, B.I. (2014) Amyloidogenic a-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol., 127, 645-665
46. Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., Lee, S., Regenhardt, R.W., McGarvey, N.H., Ayers, J.I., Notterpek, L., Borchelt, D.R. et al. (2014) Intramuscular injection of a-synuclein induces CNS a-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc. Natl. Acad. Sci. U. S. A., 111, 10732-10737
47. Giasson, B.I., Duda, J.E., Quinn, S.M., Zhang, B., Trojanowski, J.Q. and Lee, V.M.-Y. (2002) Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron, 34, 521-533
48. Rutherford, N.J., Brooks, M. and Giasson, B.I. (2016) Novel antibodies to phosphorylated a-synuclein serine 129 and NFL serine 473 demonstrate the close molecular homology of these epitopes. Acta Neuropathol. Commun., 4, 80
49. Ayers, J.I., Brooks, M.M., Rutherford, N.J., Howard, J.K., Sorrentino, Z.A., Riffe, C.J., Giasson, B.I. and Caughey, B. (2017) Robust central nervous system pathology in transgenic mice following peripheral injection of a-synuclein fibrils. J. Virol., 91, e02095-16
50. Sorrentino, Z.A., Brooks, M.M.T., Hudson, V., Rutherford, N.J., Golde, T.E., Giasson, B.I. and Chakrabarty, P. (2017) Intrastriatal injection of a-synuclein can lead to widespread synucleinopathy independent of neuroanatomic connectivity. Mol. Neurodegener., 12, 40
51. Sacino, A.N., Brooks, M., McKinney, A.B., Thomas, M.A., Shaw, G., Golde, T.E. and Giasson, B.I. (2014) Brain injection of a-synuclein induces multiple proteinopathies, gliosis, and a neuronal injury marker. J. Neurosci., 34, 12368-12378
52. Rospigliosi, C.C., McClendon, S., Schmid, A.W., Ramlall, T.F., Barré, P., Lashuel, H.A. and Eliezer, D. (2009) E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J. Mol. Biol., 388, 1022-1032
53. Brucale, M., Sandal, M., Di Maio, S., Rampioni, A., Tessari, I., Tosatto, L., Bisaglia, M., Bubacco, L. and Samorì, B. (2009) Pathogenic mutations shift the equilibria of alpha-synuclein single molecules towards structured conformers. Chembiochem, 10, 176-183
54. McKeith, I.G., Dickson, D.W., Lowe, J., Emre, M., O'Brien, J.T., Feldman, H., Cummings, J., Duda, J.E., Lippa, C., Perry, E.K. et al. (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65, 1863-1872
55. Giasson, B.I., Murray, I.V., Trojanowski, J.Q. and Lee, V.M. (2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem., 276, 2380-2386
56. Crystal, A.S., Giasson, B.I., Crowe, A., Kung, M.-P., Zhuang, Z.-P., Trojanowski, J.Q. and Lee, V.M.-Y. (2003) A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem, 86, 1359-1368
57. Giasson, B.I., Jakes, R., Goedert, M., Duda, J.E., Leight, S., Trojanowski, J.Q. and Lee, V.M. (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J. Neurosci. Res., 59, 528-533
58. Waxman, E.A., Duda, J.E. and Giasson, B.I. (2008) Characterization of antibodies that selectively detect alpha-synuclein in pathological inclusions. Acta Neuropathol., 116, 37-46
59. Duda, J.E., Giasson, B.I., Mabon, M.E., Lee, V.M.-Y. and Trojanowski, J.Q. (2002) Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann. Neurol., 52, 205-210